Targeting of naproxen covalently linked to HSA to sinusoidal cell types of the liver

BN Melgert*, C Lebbe, E Wartna, G Molema, K Poelstra, C Albrecht, J Reichen, DKF Meijer

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingConference contributionAcademicpeer-review


We have coupled the anti-inflammatory drug naproxen (Nap) covalently to human serum albumin (HSA) to deliver this drug selectively to non parenchymal cell types of the liver during endotoxin induced hepatic inflammation. Liver endothelial cells and Kupffer cells play an important role in the pathogenesis of acute and chronic inflammatory liver diseases. Targeting Nap to these cells might increase the efficacy of this drug in the treatment of these diseases and reduce its side effects. During acute inflammation in male rats, induced by endotoxin, livers showed an increased uptake of Nap when coupled to HSA as compared to free Nap. 3 hours after administering 24 mg/kg Nap(23)-HSA 28% of the dose was found in the liver versus 1.1% of a therapeutic dose of 50 mg/kg Nap (p

In conclusion, during endotoxin induced inflammation the distribution of Nap as a Nap(23)-HSA conjugate to the liver is enhanced as compared to free Nap. Moreover, Nap liberated from the albumin carrier by proteolytic degradation exhibits a longer residence time in the liver, as compared to free Nap.

Original languageEnglish
Title of host publicationCELLS OF THE HEPATIC SINUSOID, VOL 6
EditorsE Wisse, DL Knook, C Balabaud
Place of PublicationLEIDEN
PublisherThe Kupffer Cell Foundation
Number of pages2
ISBN (Print)90-803856-1-1
Publication statusPublished - 1997
Event8th International Symposium on the Cells of the Hepatic Sinusoid - , France
Duration: 1-Sep-19965-Sep-1996


Other8th International Symposium on the Cells of the Hepatic Sinusoid

Cite this